Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: Analysis of VHL dependent and VHL independent pathways of tumorigenesis

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 3, 2000, Pages 137-144

  Martinez, A ^a   Fullwood, P ^a   Kondo, K ^b   Kishida, T ^b   Yao, M ^b   Maher, E R ^a   Latif, F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chromosome 3p; Loss of heterozygosity; Renal cell carcinoma; VHL

Indexed keywords

ARTICLE; CANCER GENETICS; CHROMOSOME 3P; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 3; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; LIGASES; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0034116801     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.3.137     Document Type: Article

References (52)

1. 1 Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of chromosome-3 in renal-cell carcinoma. Nature 1987;327:721-4.
2. 2 Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A 1988;85:1571-5.
3. 3 van der Hout AH, Kok K, van den Berg A, et al. Direct molecular analysis of a deletion of 3p in tumours from patients with sporadic renal cell carcinoma. Cancer Genet Cytogenet 1988;32:281-5.
4. 4 Hosoe S, Brauch H, Latif F, et al. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 1990;8:634-40.
5. 5 Maher ER, Bently E, Yates JRW, et al. Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis. Genomics 1991;10: 957-60.
6. 6 Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
7. 7 Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-63
8. 8 Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 1995;25:219-32.
9. 9 Maher ER, Kaelin WG. Von Hippel-Lindau disease. Medicine 1997;76:381-91.
10. 10 Gnarra JR, Tory K, Weng Y, et al. Mutation of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
11. 11 Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
12. 12 Herman JH, Latif F, Weng Y, et al. Silencing of the VHL tumour suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
13. 13 Prowse AH, Webster AR, Richards FM, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-71.
14. 14 Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumorigenesis. Genes Chromosomes Cancer 1998;22:200-9.
15. 15 Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
16. 16 Schmidt L, Junker K, Kakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
17. 17 Iliopoulos O, Kibel A, Gray S, et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
18. 18 Van den Berg A, Hulsbeek MF, de Jong D, et al. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes Chromosomes Cancer 1996;15:64-72
19. 19 Killary AM, Wolf ME, Giambernardi TA, et al. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci U S A 1992;89: 10877-81.
20. 20 Sanchez Y, Elnaggar A, Pathak S, et al. A tumor suppressor locus within 3p14· p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci U S A 1994;91:3383-7.
21. 21 Daly MC, Xiang RH, Buchhagen D, et al. A homozygaus deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 1993;8:1721-9.
22. 22 Kok K, van den Berg A, Veldhuis PM, et al. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res 1994;54:4183-7.
23. 23 Wei MH, Latif F, Bader S, et al. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 1996;56:1487-92.
24. 24 Sekido Y, Mohsen A, Wistuba H, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998; 16:3151-7.
25. 25 Latif F, Tory K, Modi W, et al. Molecular characterization of a large homozygous deletion in the small cell lung cancer line U2020: a strategy for cloning the putative tumor suppressor gene. Genes Chromosomes Cancer 1992;5: 119-27.
26. 26 Sundaresan V, Chung G, Heppell-Parton A, et al. Homozygous deletions at 3p12 in breast and lung cancer. Oncogene 1998;17:1723-9.
27. 27 Lott ST, Lovell M, Naylor SL, et al. Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. Cancer Res 1998;58: 3533-7.
28. 28 Lovell M, Lott ST, Wong P, et al. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Cancer Res 1999;59:2182-9.
29. 29 Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9.
30. 30 Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
31. 31 Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
32. 32 Druck T, Hadaczek P, Fu TB, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-12.
33. 33 Fong KM, Biesterveld EJ, Virmani A, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-67.
34. 34 Huebner K, Hadaczek P, Siprashvili Z, et al. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1997;1332:M65-70.
35. 35 Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125-43.
36. 36 Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-5.
37. 37 Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93: 9821-6.
38. 38 Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
39. 39 Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
40. 40 Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-6.
41. 41 Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997;94: 2156-61.
42. 42 Lonergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18: 732-41.
43. 43 Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
44. 44 Liakopoulos D, Busgen T, Brychzy A, et al. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci U S A 1999;96:5510-15.
45. 45 Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-94.
46. 46 Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-9.
47. 47 Siemeister G, Weindel K, Mohrs K, et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56: 2299-301.
48. 48 Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Molecular Cell 1998;1:959-68.
49. 49 Sekido Y, Bader S, Latif F, et al. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 1996;93:4120-4125.
50. 50 Sithanandam G, Latif F, Duh FM, et al. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol 1996;16:868-76.
51. 51 Latif F, Duh FM, Bader S, et al. The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21. Hum Genet 1997;99:334-41.
52. 52 Clifford SC, Walsh S, Hewson K, et al. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes Cancer 1999;26:20-8.